CeriBell, Inc. (CBLL) News
Follow CeriBell, Inc. (CBLL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Ceribell shares fall as larger-than-expected loss outweighs strong revenue
Ceribell shares fell in premarket trading after a larger-than-expected loss overshadowed strong revenue. The supplied report does not specify the move's magnitude.
EARNINGS | Nov 04, 2026, 01:50 PM UTC
M
CeriBell Reports Q3 Revenue Growth and Raises 2026 Guidance
CeriBell reported third-quarter revenue of $29.3 million, up 30% year over year, with a net loss of $21.4 million and an Adjusted EBITDA loss of $12.1 million. It raised full-year 2026 revenue guidance to $115 million–$1
EQUITY | Nov 03, 2026, 10:51 PM UTC
M
CeriBell Posts Q3 Loss of $0.55 vs FactSet Estimate of $0.51 Loss
EQUITY | Nov 03, 2026, 10:50 PM UTC
L
CeriBell Reports Results for Quarter Ended September 30
EARNINGS | Nov 03, 2026, 10:48 PM UTC
M
CeriBell Reports Q3 Revenue of $29.3 Million
CeriBell reported Q3 revenue of $29.3 million, versus the FactSet estimate of $29.2 million.
EQUITY | Nov 03, 2026, 09:43 PM UTC
M
Ceribell Raises 2026 Revenue Guidance to $115M–$117M
Q3 2026 revenue rose 30% year over year to $29.3 million. Net loss was $21.4 million, compared with $13.5 million a year earlier.
EARNINGS | Nov 03, 2026, 09:31 PM UTC
M
Ceribell Reports Third-Quarter 2026 Financial Results
Ceribell reported financial results for the quarter ended September 30, 2026.
EQUITY | Nov 03, 2026, 09:08 PM UTC
M
CeriBell to Release Q3 2026 Results After Market Close Nov. 3
CeriBell will host a results call at 4:30 p.m. ET on Nov. 3, 2026.
EQUITY | Oct 20, 2026, 08:07 PM UTC
L
Ceribell (CBLL) Secures FDA 510(k) for Quantitative EEG Trending
Ceribell received FDA 510(k) clearance for software adding quantitative EEG trending and amplitude-integrated EEG, with no age restriction. The company expects an automatic software rollout in H1 2027.Material DetailsCon
REGULATION | Sep 30, 2026, 11:09 AM UTC
L
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indicationsSUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc.
REGULATION | Sep 30, 2026, 11:08 AM UTC
L
CeriBell shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance above
CeriBell shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance above estimates.
EARNINGS | Aug 11, 2026, 07:34 PM UTC
L
CeriBell Raises FY2026 Sales Guidance from $112.000M-$116.000M to $114.000M-$117.000M vs $113.979M Est
CeriBell (NASDAQ: CBLL ) raises FY2026 sales outlook from $112.000 million-$116.000 million to $114.000 million-$117.000 million vs $113.979 million estimate.
EARNINGS | Aug 10, 2026, 08:09 PM UTC
H
Ceribell Secures CMS New Technology Add-On Payment
Ceribell gets CMS payment for delirium monitor system
EQUITY | Aug 03, 2026, 11:00 AM UTC
L
Ceribell Expands Board
Ceribell appoints new board members
EQUITY | Jul 29, 2026, 11:00 AM UTC
L
CBLL - Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
CBLL - Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
EQUITY | Jul 28, 2026, 08:05 PM UTC